|
The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ipsen; Lexicon; Novartis |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Lilly; Lilly (Inst); Merck Serono; Merck Serono (Inst); MSD; MSD (Inst); Mylan; Mylan (Inst); Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Roche; Roche (Inst); Synta; Synta (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Bayer; Pfizer |
Travel, Accommodations, Expenses - Amgen; Bayer; Pfizer; Roche |
|
|
Consulting or Advisory Role - Ipsen |
Research Funding - Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Lilly; Merck Serono; Roche; Sanofi |
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Pfizer; Roche |
Travel, Accommodations, Expenses - Amgen; Merck Serono; Pfizer; Roche; Sanofi; SERVIER |
|
|
|
Consulting or Advisory Role - AbbVie; Lilly |
Research Funding - Abbvie; Specialised Therapeutics |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Ipsen |
Research Funding - Ipsen; Merck; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Ipsen; Novartis; Pfizer |
|
|
Honoraria - Amgen; Pfizer; Roche; Sanofi |
Research Funding - Amgen (Inst); Janssen Oncology (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Merck Serono; Novartis; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Consulting or Advisory Role - Novartis/Ipsen |
Research Funding - Novartis (Inst) |